Amylin Pharmaceuticals (AMLN +10.8%) continues to soar (previously) following the FDA's approval...


Amylin Pharmaceuticals (AMLN +10.8%) continues to soar (previously) following the FDA's approval of its Bydureon diabetes drug, developed in partnership with Alkermes (ALKS +1.3%). Piper (Overweight) thinks Bydureon's dosing flexibility gives it an edge over Novo Nordisk's (NVO) Victoza drug, and that FDA approval paves the way for an international licensing deal or acquisition.

From other sites
Comments (1)
  • jeichmeier
    , contributor
    Comments (5) | Send Message
     
    See my comments under "Amylin Gets Its Yes; Now For The Hard Work" article. In time Bydureon will take over market due to dosing schedual and less side effects.
    2 Feb 2012, 02:37 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Hub
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs